Compare Organon & Co. Common Stock (OGN) vs VanEck Semiconductor ETF (SMH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs VanEck Semiconductor ETF — how do they compare? Organon & Co. Common Stock trades at $13.73 (market cap $3.61B), while VanEck Semiconductor ETF trades at $553.65 (market cap $71.21B). The key difference: VanEck Semiconductor ETF is far larger — about 19.7× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while VanEck Semiconductor ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and VanEck Semiconductor ETF for 102 Days on average.
| OGN | SMH | |
|---|---|---|
Market Cap | $3.61B | $71.21B |
Volume | 1,808,049 | 11,805,201 |
Sector | Health | — |
52-Week High | $13.81 | $668.91 |
52-Week Low | $5.70 | $325.10 |
Typical Hold Time | 0 Days | 102 Days |
Enterprise Value | $11.03B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
SMH (VanEck Semiconductor ETF) trades at $588.12, down 0.49% on the day, with technical indicators showing mixed signals - a bullish overall signal but bearish moving averages. The semiconductor sector has been a standout performer in 2026, with SMH delivering approximately 69% returns year-to-date according to The Motley Fool (2026-10-01). Recent sector strength is supported by AI-driven demand and major acquisitions like AMD's $8.2 billion World Labs purchase.
The semiconductor ETF offers diversified exposure to the AI hardware boom, though concentration in top holdings like Nvidia presents both opportunity and risk. Sector rotation concerns and valuation pressures after strong gains represent near-term headwinds, while long-term growth prospects remain favorable given Bank of America's projection of near-doubling global chip market by 2030.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About VanEck Semiconductor ETF
The fund normally invests at least 80% of its total assets in securities that comprise the target index. The index includes common stocks and depositary receipts of US exchange-listed companies in the semiconductor industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a US exchange. The fund is non-diversified.
Read more on SMH →
